See the DrugPatentWatch profile for Adasuve
Adasuve, a medication used to treat agitation associated with schizophrenia and bipolar I disorder in adults, has received mixed reviews. While some patients and healthcare providers report positive outcomes, others have raised concerns about its efficacy and side effects.
What is Adasuve and how does it work?
Adasuve is an inhaled formulation of loxapine, an antipsychotic medication. It is administered via a handheld inhaler designed for rapid delivery to the lungs, allowing for quick absorption into the bloodstream and a faster onset of action compared to oral medications [1]. The drug is intended for short-term use in acute agitation [1].
What are the reported side effects of Adasuve?
The most significant safety concern associated with Adasuve is bronchospasm, which can be severe and potentially life-threatening. Cases of respiratory distress, including wheezing, coughing, and shortness of breath, have been reported [1][2]. Due to this risk, Adasuve is contraindicated in patients with a history of asthma, COPD, or other respiratory conditions [1]. Other reported side effects include drowsiness, dizziness, and changes in taste [1].
Has Adasuve faced regulatory challenges?
Yes, Adasuve has encountered regulatory hurdles. Initially approved by the U.S. Food and Drug Administration (FDA) in 2013, its approval was later withdrawn in 2017 due to safety concerns, primarily related to bronchospasm [2]. The manufacturer resubmitted data to the FDA, and the drug was reapproved in 2019 with a Risk Evaluation and Mitigation Strategy (REMS) program to manage its potential risks [2]. This REMS program includes protocols for administration and monitoring to mitigate the risk of bronchospasm [1].
How does Adasuve compare to other agitation treatments?
Adasuve offers a rapid-acting, inhaled option for managing acute agitation. This can be an advantage over oral medications, which may take longer to be absorbed and take effect. However, its use is limited by the risk of bronchospasm, making it unsuitable for patients with respiratory conditions. Other treatment options for agitation include oral antipsychotics, benzodiazepines, and intramuscular injections of antipsychotics or sedatives, each with their own efficacy and side effect profiles [1].
When does Adasuve's patent expire?
Information regarding the specific patent expiration dates for Adasuve can be found on DrugPatentWatch.com [3]. Patent information is crucial for understanding when generic versions of the drug may become available.
What are the patient experiences with Adasuve?
Patient reviews and clinical trial data suggest that Adasuve can be effective in rapidly reducing agitation in some individuals. However, concerns about the delivery device, the potential for airway irritation, and the lingering effects of the medication have also been noted [1][2]. The decision to use Adasuve is typically made on a case-by-case basis by healthcare professionals, weighing the benefits of rapid symptom control against the potential risks.
*
**Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.accessdata.fda.gov/
[3] https://www.drugpatentwatch.com/